Table 1 Patients and tumour characteristics for 199 lung cancer patients scheduled for treatment with erlotinib

Gender

Male

101

51

Female

98

49

Ethnicity

Asian

1

<1

Caucasian

198

>99

Smoking history

Current smoker

64

32

Former smoker

118

59

Never smoker

17

9

ECOG performance status*

0

26

13

1

99

49

2

63

32

3

11

6

Tumour type

Adenocarcinoma

190

95

Adenosquamous carcinoma

9

5

Tumour stage

IIA + IIB

2

1

IIIA + IIIB

29

15

IV

168

84

Erlotinib therapy

First-line

22

11

Second-line

156

78

Third-line

16

8

Fourth-line

5

3

Age (years, mean (range))

64 (33–87)